The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype

Hereditary Cancer in Clinical Practice

Volumn 7, Issue 1, 2009, Pages

  Ruijs, Marielle W G ^a,b   Broeks, Annegien ^a   Menko, Fred H ^b   Ausems, Margreet G E M ^c   Wagner, Anja ^d   Oldenburg, Rogier ^d   Meijers Heijboer, Hanne ^b,d   van't Veer, Laura J ^a   Verhoef, Senno ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CANCER SCREENING; CHILD; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NUCLEOTIDE SEQUENCE; PEDIGREE; PHENOTYPE;

EID: 79551525718     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-7-4     Document Type: Article

References (41)

1. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med 1969, 71:747-752.
2. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48:5358-5362.
3. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994, 54:1298-1304.
4. Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995, 25:101-124.
5. Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugieres L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008, 45:535-538. 10.1136/jmg.2008.057570, 18511570.
6. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238. 10.1126/science.1978757, 1978757.
7. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 1990, 28:622-629.
8. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003, 21:313-320. 10.1002/humu.10185, 12619118.
9. Bartek J, Falck J, Lukas J. CHK2 kinase - a busy messenger. Nat Rev Mol Cell Biol 2001, 2:877-886. 10.1038/35103059, 11733767.
10. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286:2528-2531. 10.1126/science.286.5449.2528, 10617473.
11. Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R. Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 2001, 85:209-212. 10.1054/bjoc.2001.1858, 11461078.
12. Bougeard G, Limacher JM, Martin C, Charbonnier F, Killian A, Delattre O, Longy M, Jonveaux P, Fricker JP, Stoppa-Lyonnet D, Flaman JM, Frebourg T. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet 2001, 38:253-257. 1734839, 11370630, 10.1136/jmg.38.4.253.
13. Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DA. Destabilization of CHK2 by a missense mutation associated with Li- Fraumeni Syndrome. Cancer Res 2001, 61:8062-8067.
14. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001, 61:5718-5722.
15. Sodha N, Houlston RS, Bullock S, Yuille MA, Chu C, Turner G, Eeles RA. Increasing evidence that germline mutations in CHEK2 do not cause Li- Fraumeni syndrome. Hum Mutat 2002, 20:460-462. 10.1002/humu.10136, 12442270.
16. Siddiqui R, Onel K, Facio F, Nafa K, Diaz LR, Kauff N, Huang H, Robson M, Ellis N, Offit K. The TP53 mutational spectrum and frequency of CHEK21100delC in Li-Fraumeni-like kindreds. Fam Cancer 2005, 4:177-181. 10.1007/s10689-004-1946-5, 15951970.
17. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295:1379-1388. 10.1001/jama.295.12.1379, 16551709.
18. Evans DG, Birch JM, Narod SA. Is CHEK2 a cause of the Li-Fraumeni syndrome?. J Med Genet 2008, 45:63-64. 10.1136/jmg.2007.054700, 18178638.
19. Meijers-Heijboer H, Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR. Low-penetrance susceptibility to breast cancer due to CHEK21100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31:55-59. 10.1038/ng879, 11967536.
20. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71:432-438. 379177, 12094328, 10.1086/341943.
21. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK21100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008, 26:542-548. 10.1200/JCO.2007.12.5922, 18172190.
22. Offit K, Garber JE. Time to check CHEK2 in families with breast cancer?. J Clin Oncol 2008, 26:519-520. 10.1200/JCO.2007.13.8503, 18172189.
23. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, Bos R, de Snoo A, Tjon AF, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, Ouweland A, Chapman P, Tops C, Moslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M. The CHEK21100delC Mutation Identifies Families with a Hereditary Breast and Colorectal Cancer Phenotype. Am J Hum Genet 2003, 72:1308-1314. 1180284, 12690581, 10.1086/375121.
24. Osorio A, Rodriguez-Lopez R, Diez O, de la Hoya M, Ignacio Martinez J, Vega A, Esteban-Cardenosa E, Alonso C, Caldes T, Benitez J. The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population. Int J Cancer 2004, 108:54-56. 10.1002/ijc.11414, 14618615.
25. Hogervorst FBL, Nederlof PM, Gille JJP, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G. Large Genomic Deletions and Duplications in the BRCA1 Gene Identified by a Novel Quantitative Method. Cancer Research 2003, 63:1449-1453.
26. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, Russell NS, van't Veer LJ. Excess risk for contralateral breast cancer in CHEK21100delC germline mutation carriers. Breast Cancer Res Treat 2004, 83:91-93. 10.1023/B:BREA.0000010697.49896.03, 14997059.
27. Hubbard T, Andrews D, Caccamo M, Cameron G, Chen Y, Clamp M, Clarke L, Coates G, Cox T, Cunningham F, Curwen V, Cutts T, Down T, Durbin R, Fernandez-Suarez XM, Gilbert J, Hammond M, Herrero J, Hotz H, Howe K, Iyer V, Jekosch K, Kahari A, Kasprzyk A, Keefe D, Keenan S, Kokocinsci F, London D, Longden I, McVicker G, Melsopp C, Meidl P, Potter S, Proctor G, Rae M, Rios D, Schuster M, Searle S, Severin J, Slater G, Smedley D, Smith J, Spooner W, Stabenau A, Stalker J, Storey R, Trevanion S, Ureta-Vidal A, Vogel J, White S, Woodwark C, Birney E. Ensembl 2005. Nucleic Acids Res 2005, 33:D447-D453. 540092, 15608235, 10.1093/nar/gki138.
28. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O, Bremer M, Karstens JH, Sohn C, Dork T. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 2005, 116:263-266. 10.1002/ijc.21022, 15810020.
29. Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P, Aittomaki K, Holli K, Blomqvist C, Kallioniemi OP, Bartek J, Nevanlinna H. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004, 111:543-547. 10.1002/ijc.20299, 15239132.
30. Gorski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbanski K, Mitus J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Debniak T, Toloczko-Grabarek A, Medrek K, Masojc B, Mierzejewski M, Kowalska E, Narod SA, Lubinski J. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 2005, 92:19-24. 10.1007/s10549-005-1409-1, 15980987.
31. Dufault MR, Betz B, Wappenschmidt B, Hofmann W, Bandick K, Golla A, Pietschmann A, Nestle-Kramling C, Rhiem K, Huttner C, von LC, Dall P, Kiechle M, Untch M, Jonat W, Meindl A, Scherneck S, Niederacher D, Schmutzler RK, Arnold N. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 2004, 110:320-325. 10.1002/ijc.20073, 15095295.
32. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004, 75:1131-1135. 1182149, 15492928, 10.1086/426403.
33. Stone JG, Eeles RA, Sodha N, Murday V, Sheriden E, Houlston RS. Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10. Cancer Lett 1999, 147:181-185. 10.1016/S0304-3835(99)00291-8, 10660104.
34. Burt EC, McGown G, Thorncroft M, James LA, Birch JM, Varley JM. Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li- Fraumeni syndrome. Br J Cancer 1999, 80:9-10. 10.1038/sj.bjc.6690313, 10389970.
35. Portwine C, Lees J, Verselis S, Li FP, Malkin D. Absence of germline p16(INK4a) alterations in p53 wild type Li-Fraumeni syndrome families. J Med Genet 2000, 37:E13. 1734649, 10922393, 10.1136/jmg.37.8.e13.
36. Brown LT, Sexsmith E, Malkin D. Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing. Cancer Genet Cytogenet 2000, 123:65-68. 10.1016/S0165-4608(00)00303-4, 11120338.
37. Barlow JW, Mous M, Wiley JC, Varley JM, Lozano G, Strong LC, Malkin D. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Cancer Epidemiol Biomarkers Prev 2004, 13:1403-1406.
38. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602. 10.1016/j.cell.2004.11.022, 15550242.
39. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T. Impact of the MDM2 SNP309 and TP53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2005, 1904480, 16258005.
40. Tabori U, Malkin D. Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res 2008, 68:2053-2057. 10.1158/0008-5472.CAN-07-2091, 18381406.
41. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, Van't Veer LJ. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007, 15:110-114. 10.1038/sj.ejhg.5201715, 17003841.